Related Experiment Video
Updated: Feb 20, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
[BIOLOGIC THERAPY FOR JUVENILE IDIOPATHIC ARTHRITIS]
1Department of Pediatrics and Pediatric Rheumatology Service, Ruth Rappaport Children Hospital, Rambam Medical Center, Haifa.
Biologic agents offer a new treatment for Juvenile Idiopathic Arthritis (JIA), selectively targeting inflammation. This review details available biologic drugs in Israel, their pediatric indications, efficacy, and safety.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Pharmacology
Background:
- Juvenile Idiopathic Arthritis (JIA) is a group of inflammatory disorders with no cure.
- Current treatments like NSAIDs and DMARDs benefit only some patients.
- Biologic agents selectively inhibit key inflammatory mediators.
Purpose of the Study:
- To review available biologic agents for JIA in Israel.
- To provide updated information on indications, efficacy, and safety in pediatric patients.
Main Methods:
- Literature review of biologic agents used in pediatric rheumatology.
- Analysis of current data on JIA treatment with biologics.
Main Results:
- Description of biologic agents currently available in Israel.
- Summary of efficacy and safety profiles for pediatric JIA treatment.
Conclusions:
- Biologic drugs represent a significant advancement in treating pediatric rheumatic disorders.
- Further research and monitoring are essential for optimizing biologic therapy in JIA.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
The JAK-STAT Signaling Pathway
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

